会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • UREA DERIVATIVES WITH ANTIPROTEOLYTIC ACTIVITY
    • HARNSTOFFVERBINDUNGEN MIT ANTIPROTEOLYTISCHER WIRKUNG
    • EP1423357B1
    • 2006-09-06
    • EP02758230.3
    • 2002-06-12
    • Sanofi-Aventis Deutschland GmbH
    • SCHUDOK, ManfredKLINGLER, OtmarNESTLER, Hans-PeterMATTER, HansSCHREUDER, HermanSZILLAT, Hauke
    • C07C275/42C07D333/38A61K31/17A61P7/00
    • C07C275/42C07C2601/14C07D333/38
    • The present invention relates to compounds of the formula I, in which R?1, R2, R4, R5, D¿1, D2, X1, X2, X3, A and B have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of thromboembolic diseases and restenoses. They are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    • 本发明涉及式Ⅰ化合物,其中R 1,R 2,R 4,R 5,D 1,D 2,X 1,X 2,X 3,A和B具有 权利要求中所示的含义。 式I的化合物是有价值的药理活性化合物。 它们具有强烈的抗血栓形成作用,并且适用于例如治疗和预防血栓栓塞性疾病和再狭窄。 它们是血液凝固酶因子VIIa的可逆抑制剂,并且通常可以在其中存在不需要的因子VIIa的活性或用于治疗或预防因子VIIa的抑制的条件下使用。 本发明还涉及式I化合物的制备方法,其用途,特别是作为药物中的活性成分,以及包含它们的药物制剂。